The U.S. Food and Drug Administration (FDA) announced that the weight loss drug Contrave is one step closer to a January 2011 approval. An advisory panel determined by a 13-7 vote that the benefits of Contrave outway the potential risks.
Contrave is a combination therapy drug comprised of naltexone and bupropion. Contrave was first developed over 13 years ago to address the physiological and behavioral causes of obesity. Contrave Obesity Research recently completed a 4,500 person study which concluded results regarding its effectiveness and safety. The study found that while Contrave can have detrimental effects on cardiovascular function, it reduced food cravings, diminished blood sugar levels, reduces appetite, and increases metabolism.
Orexigan Therapeutics Inc. is a bio-pharmaceutical organization focused entirely upon the treatment of obesity and manufactures Contrave.